Page 1

NANOBIOTIX EXPANDING LIFE Nanobiotix announces first quarter operational and financial updates April 29 , 2021 . Expanded clinical data set supporting tumor agnostic potential of NBTXR3 in presentation of first results in rectal cancer at ASCO - GI 2021 • Initiated new combination study evaluating NBTXR3 activated by radiation in combination with chemotherapy in esophageal cancer and reported new preclinical data in immunotherapy at AACR RSM 2021 , providing further support for radioenhancer NBTXR3 as a therapeutic combination - agnostic that could prime adaptive immune response for local and systemic control • New collaboration agreement signed by subsidiary Curadigm with Sanofi evaluating novel Nanoprimer technology in gene therapy • Cash , cash equivalents , and short - term investments were € 107.1 million at March 31 , 2021 , continuing to support robust development plans into the second quarter of 2023 Paris , France ; Cambridge , Massachusetts ( USA ) ; April 29 , 2021 – NANOBIOTIX ( Euronext : NANO – NASDAQ : NBTX - the " Company ) , a late - stage clinical biotechnology company pioneering physics - based approaches to expand treatment possibilities for patients with cancer , today announced operational progress and cash position for the first quarter of 2021 . " The first quarter of this year saw further progress in development for Nanobiotix , " said Laurent Levy , co - founder and chief executive officer of Nanobiotix . " We continue to generate data reinforcing our vision for NBTXR3 as a first - in - class radioenhancer that could have a significant impact for patients across solid tumor types and therapeutic combinations . We are also encouraged that Sanofi has seen the potential of Curadigm's Nanoprimer and look forward to a successful collaboration between the two companies in gene therapy . " Financial Updates Supporting Nanobiotix Development and Corporate Plans Cash , cash equivalents , and short - term investments were € 107.1 million at March 31 , 2021 , supporting robust development plans into the second quarter of 2023 , compared to € 28m as of March 31st , 2020 . Following the decision to conclude a License and Collaboration agreement with PharmaEngine , Inc. , the Company did not generate any revenue during the first quarter of 2021. This compares to € 24k for the first quarter of 2020 , which resulted from cross - charges associated with the collaboration . Clinical Activities and Achievements Advancing Solid Tumor - Agnostic and Combination - Agnostic Potential of NBTXR3 • Preclinical data , developed in collaboration with the University of Texas MD Anderson Cancer Center ( MD Anderson ) , further suggesting that NBTXR3 could prime adaptive immune response and combine with several immune checkpoint inhibitors was presented at the first American Association of Cancer Research ( AACR ) Virtual Special Conference on Radiation Science and Medicine in March . This data demonstrated that a combo therapy including NBTXR3 , anti - PD - 1 , anti - TIGIT , and anti - LAG3 augmented anti - tumor response in both irradiated and unirradiated tumors , improving local and distant tumor control and increasing survival rate . The survivor mice were immune to re - injections of tumor cells , maintained significantly higher percentages of memory immune cells and stronger anti - tumor immune activities than control . • First clinical results in rectal cancer including recommended phase II dose from the complete phase lb part of a phase lb / ll study evaluating NBTXR3 activated by radiation therapy with concurrent chemotherapy were presented in January at the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium ( ASCO - GI 2021 ) . The data showed that the intra - tumoral injection of NBTXR3 was feasible and well tolerated at all dose levels . More than 70 % of patients showed objective tumor response and approximately 90 % of patients underwent total mesorectal excision ( surgery ) , and 17.6 % achieved pathological complete response . In addition , 50 % of the patients receiving surgery had good tumor regression . PharmaEngine , Inc. will implement the termination and wind - down of the phase II part of this clinical study pursuant to the agreement regarding the conclusion of this collaboration . • First patient injected in esophageal cancer , a new indication for NBTXR3 , in a phase I study evaluating NBTXR3 activated by radiation therapy with concurrent chemotherapy ( Study 2020-0122 ) in January . The trial is being conducted with MD Anderson as part of an ongoing clinical collaboration . Corporate Activities and Achievements Expanding Value Creation Opportunities for Nanobiotix • Collaboration agreement between Sanofi and Nanobiotix subsidiary , Curadigm , in January . Pursuant to Sanofi's